Y10S 424/804
Involving igg3, igg4, iga, or igy
Official title: involving IgG3, IgG4, IgA, or IgY
Y10S424/804 (Involving igg3, igg4, iga, or igy) appears on 53 US grants and 5 published applications in this corpus.
Search patents in Y10S- Granted patents
- 53
- Published applications
- 5
- Assignees
- 36
- Inventors
- 95
- Latest grant
- 22 Feb 2011
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1976 | 1 | 0 |
| 1977 | 0 | 0 |
| 1978 | 0 | 0 |
| 1979 | 0 | 0 |
| 1980 | 0 | 0 |
| 1981 | 0 | 0 |
| 1982 | 1 | 0 |
| 1983 | 0 | 0 |
| 1984 | 1 | 0 |
| 1985 | 1 | 0 |
| 1986 | 0 | 0 |
| 1987 | 1 | 0 |
| 1988 | 3 | 0 |
| 1989 | 6 | 0 |
| 1990 | 7 | 0 |
| 1991 | 2 | 0 |
| 1992 | 6 | 0 |
| 1993 | 3 | 0 |
| 1994 | 2 | 0 |
| 1995 | 2 | 0 |
| 1996 | 2 | 0 |
| 1997 | 1 | 0 |
| 1998 | 3 | 0 |
| 1999 | 1 | 0 |
| 2000 | 0 | 0 |
| 2001 | 1 | 0 |
| 2002 | 1 | 0 |
| 2003 | 3 | 0 |
| 2004 | 1 | 1 |
| 2005 | 0 | 1 |
| 2006 | 0 | 0 |
| 2007 | 1 | 1 |
| 2008 | 0 | 1 |
| 2009 | 1 | 1 |
| 2010 | 1 | 0 |
| 2011 | 1 | 0 |
By publication year. Applications have been published since 2001.
Recent patents
- Monovalent ligand of the FcαRI receptor as an anti-inflammatory agent22 Feb 2011US 7,892,538 B2Institut National de la Sante et de la Recherche
- Specific avian egg antibodies for disease prevention and improvement of growth performance11 May 2010US 7,713,527 B2
- Antibodies that specifically bind to neurokinin B7 Apr 2009US 7,514,079 B2Human Genome Sciences, Inc.
- Epithelial tissue targeting agent25 Dec 2007US 7,311,912 B1Plantbodies Corporation
- Antivenom immunesera21 Dec 2004US 6,833,131 B1Protherics Inc.
- Antibodies That Specifically Bind to Neurokinin B7 May 2009US 2009/0117043 A1Human Genome Sciences, Inc.
- Monovalent ligand of the Fcalphari Receptor as an Anti-Inflammatory Agent10 Apr 2008US 2008/0085280 A1Institut National de la Sante et de la Recherche
- Antibodies as Growth Promoting Agents29 Mar 2007US 2007/0071795 A1
- Antibodies that specifically bind to neurokinin B28 Jul 2005US 2005/0163777 A1Human Genome Sciences, Inc.
- Clostridial toxin disease therapy1 Apr 2004US 2004/0062771 A1Promega Corporation
Most cited
By later US patents
- Monoclonal anti-human breast cancer antibodies226US 4,753,894 ACetus Corporation · 1988
- EX vivo effector cell activation for target cell killing92US 4,844,893 AScripps Clinic and Research Foundation · 1989
- Oral administration of chicken yolk immunoglobulins to lower somatic cell count in the milk of lactating ruminants92US 5,585,098 AOvimmune, Inc. · 1996
- Method for imaging breast tumors using labeled monoclonal anti-human breast cancer antibodies78US 4,938,948 ACetus Corporation · 1990
- Antivenoms and methods for making antivenoms70US 5,196,193 AOphidian Pharmaceuticals, Inc. · 1993